Compare TYRA & CCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | CCU |
|---|---|---|
| Founded | 2018 | 1850 |
| Country | United States | Chile |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2021 | 2001 |
| Metric | TYRA | CCU |
|---|---|---|
| Price | $26.04 | $12.07 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 11 | 2 |
| Target Price | ★ $47.50 | $12.00 |
| AVG Volume (30 Days) | ★ 630.1K | 142.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.42 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | ★ N/A | $18.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $10.71 |
| 52 Week High | $40.65 | $15.36 |
| Indicator | TYRA | CCU |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 62.51 |
| Support Level | $24.77 | $10.83 |
| Resistance Level | $32.82 | $12.11 |
| Average True Range (ATR) | 1.75 | 0.35 |
| MACD | -0.67 | 0.05 |
| Stochastic Oscillator | 7.53 | 78.90 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.